Gary W. Pace, Director at Cardiff Oncology, Inc. (CRDF), bought 150,000 shares at $1.71 ($257K) on 2022-09-15, disclosed to the SEC on 2022-09-19.
Open-market purchase of $256k CRDF by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Something here stands out, but not much.
| Filing → |
| CRDF | BUY | 2025-07-31 | $711K | — | Filing → |
| CRDF | BUY | 2024-12-12 | $940K | — | Filing → |
| PCRX | SELL | 2024-03-08 | $4.5M | — | Filing → |